OBJECTIVE: To describe the prevalence of neurocognitive impairment (NCI) among early diagnosed and managed HIV-infected persons (HIV+) compared to HIV-negative controls. METHODS: We performed a cross-sectional study among 200 HIV+ and 50 matched HIV-uninfected (HIV-) military beneficiaries. HIV+ patients were categorized as earlier (<6 years of HIV, no AIDS-defining conditions, and CD4 nadir >200 cells/mm(3)) or later stage patients (n = 100 in each group); both groups were diagnosed early and had access to care. NCI was diagnosed using a comprehensive battery of standardized neuropsychological tests. RESULTS: HIV+ patients had a median age of 36 years, 91% were seroconverters (median window of 1.2 years), had a median duration of HIV of 5 years, had a CD4 nadir of 319, had current CD4 of 546 cells/mm(3), and 64% were on highly active antiretroviral therapy (initiated 1.3 years after diagnosis at a median CD4 of 333 cells/mm(3)). NCI was diagnosed among 38 (19%, 95% confidence interval 14%-25%) HIV+ patients, with a similar prevalence of NCI among earlier and later stage patients (18% vs 20%, p = 0.72). The prevalence of NCI among HIV+ patients was similar to HIV- patients. CONCLUSIONS: HIV+ patients diagnosed and managed early during the course of HIV infection had a low prevalence of NCI, comparable to matched HIV-uninfected persons. Early recognition and management of HIV infection may be important in limiting neurocognitive impairment.
OBJECTIVE: To describe the prevalence of neurocognitive impairment (NCI) among early diagnosed and managed HIV-infectedpersons (HIV+) compared to HIV-negative controls. METHODS: We performed a cross-sectional study among 200 HIV+ and 50 matched HIV-uninfected (HIV-) military beneficiaries. HIV+ patients were categorized as earlier (<6 years of HIV, no AIDS-defining conditions, and CD4 nadir >200 cells/mm(3)) or later stage patients (n = 100 in each group); both groups were diagnosed early and had access to care. NCI was diagnosed using a comprehensive battery of standardized neuropsychological tests. RESULTS: HIV+ patients had a median age of 36 years, 91% were seroconverters (median window of 1.2 years), had a median duration of HIV of 5 years, had a CD4 nadir of 319, had current CD4 of 546 cells/mm(3), and 64% were on highly active antiretroviral therapy (initiated 1.3 years after diagnosis at a median CD4 of 333 cells/mm(3)). NCI was diagnosed among 38 (19%, 95% confidence interval 14%-25%) HIV+ patients, with a similar prevalence of NCI among earlier and later stage patients (18% vs 20%, p = 0.72). The prevalence of NCI among HIV+ patients was similar to HIV- patients. CONCLUSIONS: HIV+ patients diagnosed and managed early during the course of HIV infection had a low prevalence of NCI, comparable to matched HIV-uninfectedpersons. Early recognition and management of HIV infection may be important in limiting neurocognitive impairment.
Authors: Thomas D Marcotte; Reena Deutsch; J Allen McCutchan; David J Moore; Scott Letendre; Ronald J Ellis; Mark R Wallace; Robert K Heaton; Igor Grant Journal: Arch Neurol Date: 2003-10
Authors: Raul Gonzalez; Robert K Heaton; David J Moore; Scott Letendre; Ronald J Ellis; Tanya Wolfson; Thomas Marcotte; Mariana Cherner; Julie Rippeth; Igor Grant Journal: J Int Neuropsychol Soc Date: 2003-01 Impact factor: 2.892
Authors: N Sacktor; R H Lyles; R Skolasky; C Kleeberger; O A Selnes; E N Miller; J T Becker; B Cohen; J C McArthur Journal: Neurology Date: 2001-01-23 Impact factor: 9.910
Authors: Ned Sacktor; Michael P McDermott; Karen Marder; Giovanni Schifitto; Ola A Selnes; Justin C McArthur; Yaakov Stern; Steve Albert; Donna Palumbo; Karl Kieburtz; Joy A De Marcaida; Bruce Cohen; Leon Epstein Journal: J Neurovirol Date: 2002-04 Impact factor: 2.643
Authors: Charles H Hinkin; David J Hardy; Karen I Mason; Steven A Castellon; Ramani S Durvasula; Mona N Lam; Marta Stefaniak Journal: AIDS Date: 2004-01-01 Impact factor: 4.177
Authors: J C McArthur; D R Hoover; H Bacellar; E N Miller; B A Cohen; J T Becker; N M Graham; J H McArthur; O A Selnes; L P Jacobson Journal: Neurology Date: 1993-11 Impact factor: 9.910
Authors: Robert K Heaton; Thomas D Marcotte; Monica Rivera Mindt; Joseph Sadek; David J Moore; Heather Bentley; J Allen McCutchan; Carla Reicks; Igor Grant Journal: J Int Neuropsychol Soc Date: 2004-05 Impact factor: 2.892
Authors: David J Moore; Scott L Letendre; Sheldon Morris; Anya Umlauf; Reena Deutsch; Davey M Smith; Susan Little; Alexandra Rooney; Donald R Franklin; Ben Gouaux; Shannon Leblanc; Debra Rosario; Christine Fennema-Notestine; Robert K Heaton; Ronald J Ellis; J Hampton Atkinson; Igor Grant Journal: J Neurovirol Date: 2010-12-15 Impact factor: 2.643
Authors: Andrew C Young; Constantin T Yiannoutsos; Manu Hegde; Evelyn Lee; Julia Peterson; Rudy Walter; Richard W Price; Dieter J Meyerhoff; Serena Spudich Journal: Neurology Date: 2014-09-26 Impact factor: 9.910
Authors: Alicia González-Baeza; Fernando Carvajal; Carmen Bayón; Ignacio Pérez-Valero; Miriam Estébanez; Jose I Bernardino; Susana Monge; María Lagarde; Asunción Hernando; Francisco Arnalich; José R Arribas Journal: J Neurovirol Date: 2014-04-24 Impact factor: 2.643
Authors: Robert Deiss; Cdr Justin Campbell; Caitlin Wei-Ming Watson; Raeanne C Moore; Nancy F Crum-Cianflone; Xun Wang; Anuradha Ganesan; Lt Col Jason Okulicz; Scott Letendre; Ryan C Maves; David J Moore; Brian K Agan Journal: Psychiatry Date: 2019-03-29 Impact factor: 2.458
Authors: Brian K Agan; Anuradha Ganesan; Morgan Byrne; Robert Deiss; Christina Schofield; Ryan C Maves; Jason Okulicz; Xiuping Chu; Thomas O'Bryan; Tahaniyat Lalani; Karl Kronmann; Tomas Ferguson; Merlin L Robb; Timothy J Whitman; Timothy H Burgess; Nelson Michael; Edmund Tramont Journal: Mil Med Date: 2019-11-01 Impact factor: 1.437
Authors: Enrico G Ferro; Damian Weikum; Panagiotis Vagenas; Michael M Copenhaver; Pedro Gonzales; Jesus Peinado; Robinson Cabello; Javier R Lama; Jorge Sanchez; Frederick L Altice Journal: AIDS Care Date: 2014-10-03